Dry eye
Conditions
Interventions
DQS(diquafosol ophthalmic solution) treatment group:No
Sponsors
Xiamen Eye Center of Xiamen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with dry eye; 2. Patients who are prescribed to use 3% diquafosol ophthalmic solution by physicians; 3. Patients joined the study voluntarily and has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of allergies to any of the components of the drug or test reagent that is expected to be used in the study (e.g. diquafosol sodium and fluorescein); 2. Administration of 3% diquafosol sodium eye drops within two weeks before enrollment; 3. Patients who need to receive adjustment in topical treatment due to other reasons except for dry eye within observation period; 4. Patients who have participated in other clinical trial within one month before the study or those who are participating in other clinical trial simultaneously; 5. Patients who are judged ineligible for this study by investigator due to non-controlled systematic diseases or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FBUT(fluorescein tear film break-up time) from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in DEQS (dry eye questionnaire score) from baseline;Change in FBUT from baseline;Change in lid margin abnormal score from baseline ;Change in lipid layer thickness (only conduct in appointed sites) from baseline;Change in tear meniscus height (only conduct in appointed sites) from baseline;Change in meibomian gland examination result (only conduct in appointed sites) from baseline;Change in CFS (corneal fluorescein staining) score from baseline;Change in Schirmer I test from baseline;The percentage of patients who continue treatment; | — |
Countries
China
Contacts
Public ContactWang Wei
Santen Pharmaceutical (China) Co., Ltd.
Outcome results
None listed